Multiple Sclerosis (MS) Clinical Trials and Treatments

Multiple sclerosis (MS) is an autoimmune condition in which the body's immune system mistakenly attacks myelin, the insulating layer around nerve fibers in the central nervous system. This damage, called demyelination, creates scar tissue (sclerosis) that disrupts nerve signals. The disease follows several distinct clinical courses.

The most common symptoms of Multiple Sclerosis include Numbness or tingling in limbs, often on one side, Vision problems including optic neuritis and double vision, Fatigue that is disproportionate to activity level, Muscle weakness, spasticity, and difficulty walking, Cognitive changes including memory and concentration problems, among others. Approximately 1 million people in the U.S.; about 1 in 300. Worldwide, an estimated 2.8 million people live with MS.. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Multiple Sclerosis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Multiple sclerosis research remains among the most active areas in neurology, with trials spanning every disease subtype and stage. BTK inhibitors are the most closely watched drug class in the current pipeline.

Yes. As of September 2026, Trial Friend lists 10 FDA-approved drugs used to treat Multiple Sclerosis: Copaxone (glatiramer acetate), first approved in 1996; Tysabri (natalizumab), first approved in 2004; Gilenya (fingolimod), first approved in 2010; Aubagio (teriflunomide), first approved in 2012; Tecfidera (dimethyl fumarate), first approved in 2013; Ocrevus (ocrelizumab), first approved in 2017; Mayzent (siponimod), first approved in 2019; Zeposia (ozanimod), first approved in 2020; Kesimpta (ofatumumab), first approved in 2020; and Briumvi (ublituximab), first approved in 2022.

Each has its own page with what the label covers, side effects and how it is given, and the Treatments section of this page adds any further approved drugs found in FDA labeling data.

Multiple sclerosis is caused by a combination of genetic susceptibility and environmental triggers. Over 230 genetic variants contribute to risk, with the HLA-DRB1*15:01 allele being the strongest. Epstein-Barr virus (EBV) infection is considered a necessary trigger, with the landmark Bjornevik et al. Science 2022 study showing it increases MS risk roughly 32-fold in a 10-million-person U.S. military cohort, through molecular mimicry between the viral protein EBNA1 and brain proteins like GlialCAM. Other risk factors include vitamin D deficiency, smoking, adolescent obesity, and geographic latitude. The immune system attacks myelin in the central nervous system, but why this autoimmune process begins remains under active investigation.

Multiple sclerosis is not caused by a single gene and there is no diagnostic genetic test for MS. Over 230 genetic variants have been identified through genome-wide association studies (GWAS), with the HLA-DRB1*15:01 allele being the strongest individual risk factor, roughly tripling the odds of developing MS. However, MS is polygenic and these variants together explain only about half of estimated heritability. Polygenic risk scores are being developed in research settings but do not yet have clinical utility. Diagnosis relies on the McDonald criteria using MRI, neurological examination, and cerebrospinal fluid analysis. Epstein-Barr virus infection is considered a necessary environmental risk factor.

Eligibility for Multiple Sclerosis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Multiple Sclerosis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.

Many MS clinical trials require participants to stop or wash out from their current disease-modifying therapy (DMT) before enrolling. Trial Friend's medication conflict checker scans each trial's exclusion criteria against common MS treatments including Ocrevus (ocrelizumab), Tysabri (natalizumab), Kesimpta (ofatumumab), Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Aubagio (teriflunomide), Copaxone (glatiramer acetate), and Mavenclad (cladribine). Washout periods vary by drug and can range from weeks to months depending on the medication's mechanism and half-life. Some trials also exclude patients who have received B-cell depleting therapies within a certain timeframe. The checker flags the specific drug name, the trial's exclusion language, and a confidence level so you can discuss timing and options with your neurologist.

Key questions to ask your doctor about MS clinical trials include: Are there trials specifically for my MS subtype (RRMS, SPMS, or PPMS)? How would participating in a trial interact with my current disease-modifying therapy? Are remyelination or neuroprotection trials appropriate for my stage of disease? Could a BTK inhibitor trial be a good option given my treatment history? What biomarkers or MRI findings would help determine which trials I qualify for? The National MS Society research portal can also help identify appropriate studies.